Onco Wiki / Regime

Cinacalcet para hipercalcemia de carcinoma paratireoideo

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

Registro de base de conhecimento para auditoria. Conteúdo clínico provisório: não é uma prescrição. Um oncologista deve verificar fontes originais, aplicabilidade e estado de revisão. Regras completas e restrições estão no YAML.

Fonte YAML: registo completo

Notas

STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode- exempted draft content). Cinacalcet controls PTH-driven hypercalcemia in unresectable, recurrent, or metastatic parathyroid carcinoma; it has no direct antitumor effect. Re-resection of accessible disease, where surgically feasible, remains the preferred disease-directed intervention alongside this regimen in the recurrent/metastatic setting (see IND-PARATHYROID-CARCINOMA-2L-CINACALCET) — not encoded as a regimen component because surgical feasibility is patient/anatomy-specific, not a fixed pharmacologic step. Bisphosphonates (DRUG-ZOLEDRONATE) or denosumab (DRUG-DENOSUMAB) are complementary options for skeletal-related-event prevention in bone-metastatic disease and for hypercalcemia refractory to cinacalcet alone — not bundled into this regimen because they act on a distinct mechanism (osteoclast-mediated bone turnover vs. PTH secretion) and no fixed combination schedule is established in guidelines; use per concurrent clinical need alongside this regimen.

Usado por

Doença

• DIS-PARATHYROID-CARCINOMA - Carcinoma paratiroideo

Indicação

• IND-PARATHYROID-CARCINOMA-2L-CINACALCET - IND-PARATHYROID-CARCINOMA-2L-CINACALCET